Metastatic Poorly Differentiated Carcinoma: Aggressive Cancer of Unknown Primary

Metastatic poorly differentiated carcinoma (MPDC) is an aggressive malignancy where cancer cells have lost identifiable features of their tissue of origin.

Key Features

• Poorly Differentiated: Cells lack glandular, squamous, or other lineage markers on microscopy.
• Metastatic at Diagnosis: Spread via blood, lymph, or direct extension to lungs, liver, bone, brain, nodes.
• Unknown Primary (CUP): Often the primary site is never found despite workup.

Diagnostic Workup

• IHC panel: Keratins (AE1/AE3, CK7, CK20), CD45 (exclude lymphoma), S100 (melanoma), TF-1 (germ cell), Napsin A/TTF-1 (lung), GATA3 (breast/urothelial), etc.
• Molecular profiling (NGS) increasingly guides targeted therapy.
• PET-CT for occult primary.

Treatment

• Empiric platinum-based chemotherapy (carboplatin + taxane/gemcitabine) if no actionable target.
• Site-specific if primary inferred (e.g., neuroendocrine, germ cell).
• Immunotherapy (PD-L1 high, TMB-H, MSI-H).
• Clinical trials preferred.

Prognosis

Median survival months; highly variable. Subsets (e.g., midline carcinoma, NUT carcinoma) have specific biology. Palliative care integration early improves quality of life.